There are 2789 resources available
Q&A and live discussion
Presenter: Paolo G. Casali
Session: Rare cancers
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Rocio Garcia-Carbonero
Session: Presidential Symposium 3 – Discussion session I: NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Marie von Lilienfeld-Toal
Session: Presidential Symposium 3 – Discussion session II: Sars-CoV-2 and cancer
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
No
Presenter: Michiel van der Heijden
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
Q&A
Presenter: Arnaud Mejean
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Benjamin Besse
Session: Presidential Symposium 3 – Discussion session III: NSCLC, early stage
Resources:
Slides
Webcast
Yes
Presenter: Thomas Powles
Session: Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer?
Resources:
Slides
Webcast
LBA13 - Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
Presenter: Nadia Harbeck
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast